AP
ORIC icon

Antipodes Partners’s Oric Pharmaceuticals ORIC Stock Holding History

Antipodes Partners’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,278
Closed -$16.2K – 147
2026
Q1 		$16.2K Sell
1,278
-1,121
-47% -$12.7K ﹤0.01% 122
2025
Q4 		$19.6K Sell
2,399
-502
-17% -$5.78K ﹤0.01% 122
2025
Q3 		$34.8K Sell
2,901
-2,293
-44% -$24.1K ﹤0.01% 101
2025
Q2 		$52.7K Buy
5,194
+1,372
+36% +$9.21K ﹤0.01% 86
2025
Q1 		$21.3K Buy
+3,822
New +$33.4K ﹤0.01% 95

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Antipodes Partners's ORIC Position: Q2 2026 in Review

Antipodes Partners sold out of Oric Pharmaceuticals (ORIC) in Q2 2026, closing a stake of 1,278 shares — an estimated $16.2K sold.

Antipodes Partners first reported a position in ORIC in Q1 2025 and held it in 5 quarters. The position peaked at $52.7K in Q2 2025. 180 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Antipodes Partners reported no remaining Oric Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Antipodes Partners sold 1,278 Oric Pharmaceuticals shares in Q2 2026, an estimated $16.2K.
  • Antipodes Partners first reported a position in Oric Pharmaceuticals in Q1 2025 and held it in 5 quarters.
  • Antipodes Partners's Oric Pharmaceuticals position peaked at $52.7K in Q2 2025.
  • 180 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Antipodes Partners's 13F filing for Q2 2026, filed 6 Aug 2026.